Hyundai to release anti-oxidant therapy in 2014

Published: 2008-07-23 06:51:00

Updated: 2008-07-23 06:51:00

Hyundai Pharm has recently entered into a licensing agreement with Nippon Zoki Pharmaceutical Co. to develop and commercialize a new anti-oxidant (code name: HD003) for treatment of chronic renal failure (CRF).

According to Hyudai officials, HD003 in a tablet form may be available on the marke...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK